OIS Chicago

JULY 25, 2019
CHICAGO, IL

OIS unites 300 industry, entrepreneurial and clinical leaders to collaborate on the development and commercialization of innovative drugs and devices to address unmet clinical needs.

OIS@ASRS 2019
OIS San Francisco

OCTOBER 10, 2019
SAN FRANCISCO, CA

OIS unites over 1,000 industry, entrepreneurial and clinical leaders to collaborate on the development and commercialization of innovative drugs and devices to address unmet clinical needs.

OIS@AAO

The Ophthalmology Innovation Summits facilitate meaningful interactions and the exchange of information between clinical, capital and corporate leaders to accelerate the development and commercialization of novel therapies to address unmet needs.

LATEST NEWS

Keeping an "Eye on Innovation" Through News & Analysis

National Vision and Eye Health Surveillance System Gears Up for September Launch

National Vision and Eye Health Surveillance System Gears Up for September Launch

WASHINGTON – The national Vision and Eye Health Surveillance System (VEHSS) being built by researchers at the University of Chicago’s National Opinion Research Center (NORC) ...
OIS@ASRS at the Ritz-Carlton Chicago: An In-depth Look at the Retina Space

OIS@ASRS at the Ritz-Carlton Chicago: An In-depth Look at the Retina Space

CHICAGO – The extensive, intensive public and private investment in the retinal space will fill the day next Thursday, July 25, at the OIS@ASRS meeting, ...
OIS Index Q2 2019

OIS Index Posts Modest Gain for Q2; Ophthalmic Market Leader Alcon Joins Index

The OIS Index of ophthalmic stocks posted a modest positive return of +0.8% during the second quarter of 2019. The index outperformed the NASDAQ Biotechnology ...
A Closer Look at AbbVie-Allergan Deal and Where Eye Care Fits In

A Closer Look at AbbVie-Allergan Deal and Where Eye Care Fits In

NEW YORK – In what’s been called “a transformative move for both companies,” AbbVie has agreed to buy Allergan in a deal valued at $63 ...
Ocular Therapeutix’s Strong Bounce Back

After Re-submitted NDA a Year Ago, Ocular Therapeutix Finds Its Path Forward

In July 2018 Ocular Therapeutix re-submitted its New Drug Application for Dextenza to the Food and Drug Administration. At that time, Scott Corning, the company’s ...
Why Ophthalmology Bulls Keep Running

Why Equity and M&A Markets in Ophthalmology Are Poised for a Great Run

SAN DIEGO – Although the 10-year bull market is bound to end one of these days, the trend in ophthalmology and healthcare in general is ...

STAY UP TO DATE WITH OIS

Get the Latest News, Podcasts and Videos.